Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27481536 | 0.83 | IDO1 (0.43) | IDO1SIGMAR1MAPTHTTMEN1 | |
| SCHEMBL2170909 | 0.82 | IDO1 (0.47) | IDO1SIGMAR1MAPTHTTGRIN2D | |
| SCHEMBL526384 | 0.82 | IDO1 (0.52) | IDO1MAPTHTTMEN1KMT2A | |
| SCHEMBL21812021 | 0.80 | KMT2A (0.42) | IDO1SIGMAR1MAPTHTTMEN1 | |
| Iodide SCHEMBL27185482 | 0.79 | IDO1 (0.50) | IDO1MAPTHTTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5804938 | 0.79 | IDO1 (0.50) | IDO1MAPTHTTMEN1KMT2A | |
| SCHEMBL27602957 | 0.79 | TLR8 (0.46) | MAPTHTTPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL18576413 | 0.76 | IDO1 (0.44) | IDO1MAPTHTTMEN1KMT2A | |
| SCHEMBL1168220 | 0.75 | IDO1 (0.52) | IDO1MAPTHTTMEN1KMT2A | |
| SCHEMBL16432444 | 0.74 | MAPT (0.38) | IDO1SIGMAR1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065698-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| WO-2010131274-A1 | PROCESS FOR PREPARING HYDROCINNAMIC ALDEHYDES IN ENANTIOPURE OR ENANTIOMERICALLY ENRICHED FORM | ENDURA S.P.A (IT) | 2010-11-18 | — | — | WO | disclosed |
| EP-2139468-A1 | HEXAHYDRO-CYCLOOCTYL PYRAZOLE CANNABINOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009023292-A1 | HEXAHYDRO-CYCLOOCTYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-02-19 | — | — | WO | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008098859-A1 | HCV POLYMERASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
| EP-1888524-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1866034-A1 | SUBSTITUTED 1,2-ETHYLENDIAMINES, MEDICAMENTS COMPRISING SAID COMPOUND; THEIR USE AND THEIR METHOD OF MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006117677-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006103038-A1 | SUBSTITUTED 1,2-ETHYLENDIAMINES, MEDICAMENTS COMPRISING SAID COMPOUND; THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065698-A1 | NOVEL PROTEIN KINASE MODULATORS | PIM2, PIM1, PIM3 | IDO1 1596/4885SIGMAR1 3915/4885MAPT 3965/4885 |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | PIM2, PIM1, PIM3 | IDO1 1892/4885SIGMAR1 3313/4885MAPT 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.